Skip to main content
. Author manuscript; available in PMC: 2023 May 23.
Published in final edited form as: Lancet Infect Dis. 2021 Apr 14;21(8):1120–1128. doi: 10.1016/S1473-3099(21)00142-0

Figure 1: Study sites and prevalence of Pfkelch13 mutations in pre-treatment samples by study site.

Figure 1:

This study was done in three Rwandan health centres: Rukara (Kayonza Distric), Masaka (Kicukiro District) and Bugarama (Rusizi District). The prevalence of the Pfkelch13 R561H mutation was found in ten (20%) of 51 samples in Masaka, and eight (22%) of 82 in Rukara; that of the P574L marker was two (1%) of 82 samples in Rukara. Prevalence of the candidate artemisinin partial resistance markers was one (2%) of 51 samples in Masaka, three (4%) of 82 samples in Rukara, and one (1%) of 85 samples in Bugarama.